Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Injury promotes sarcoma development in a genetically and temporally restricted manner
David Van Mater, … , Sandeep Dave, David G. Kirsch
David Van Mater, … , Sandeep Dave, David G. Kirsch
Published October 18, 2018
Citation Information: JCI Insight. 2018;3(20):e123687. https://doi.org/10.1172/jci.insight.123687.
View: Text | PDF
Research Article Oncology

Injury promotes sarcoma development in a genetically and temporally restricted manner

  • Text
  • PDF
Abstract

Cancer results from the accumulation of genetic mutations in a susceptible cell of origin. We and others have also shown that injury promotes sarcoma development, but how injury cooperates with genetic mutations at the earliest stages of tumor formation is not known. Here, we utilized dual recombinase technology to dissect the complex interplay of the timing of KrasG12D activation, p53 deletion, and muscle injury in sarcomagenesis using a primary mouse model of soft tissue sarcoma. When mutations in oncogenic Kras and p53 are separated by 3 weeks, few sarcomas develop without injury. However, the transformation potential of these tumor-initiating cells can be unmasked by muscle injury. In the absence of Kras mutations, injury of the muscle with global deletion of p53 results in sarcomas with amplification of chromosomal regions encompassing the Met or Yap1 gene. These findings demonstrate a complex interplay between the timing of genetic mutations and perturbations in the tumor microenvironment, which provides insight into the earliest stages of sarcoma development.

Authors

David Van Mater, Eric Xu, Anupama Reddy, Leonor Añó, Mohit Sachdeva, Wesley Huang, Nerissa Williams, Yan Ma, Cassandra Love, Lanie Happ, Sandeep Dave, David G. Kirsch

×

Figure 4

Timing of Kras activation and injury determines the penetrance of sarcoma development in mice following systemic p53 deletion.

Options: View larger image (or click on image) Download as PowerPoint
Timing of Kras activation and injury determines the penetrance of sarcom...
(A) Schematic of experiment. R26CreER; p53fl; KFRT mice were treated with IP tamoxifen (deletes p53) on day 0, followed by IM adeno-FlpO on day 0 or 21. An additional group of mice was treated with IM adeno-FlpO and IM cardiotoxin on day 21. (B) Survival curve reveals delayed kinetics and decreased penetrance when Kras signaling is not activated on the same day as p53 deletion. Sarcoma kinetics and penetrance are restored to baseline when IM adeno-FlpO and IM cardiotoxin are coadministered on day 21. ****P < 0.0001 by log-rank test. (C) Schematic of experiment. R26CreER; p53fl; KFRT and R26CreER; p53fl mice were treated with IP tamoxifen on day 0, followed by IM cardiotoxin on days 0, 1, 3, 7, and 21. (D) Survival curve shows delayed kinetics and decreased penetrance of sarcoma formation when IM cardiotoxin administration is delayed following IP tamoxifen.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts